Clinical Trial

Axi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B Lymphoma Ineligible to Autologous Stem Cell Transplantation

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a phase 2, open-label, multicenter study evaluating axicabtagene ciloleucel (axi-cel) as a 2nd line therapy in patients with Relapsed/Refractory aggressive B-NHL who are ineligible to receive Autologous Stem Cell Transplantation but eligible to receive CAR T-cell therapy.
Protocol Amendment History 13 amendments
This ClinicalTrials.gov record has been amended 13 times since 2020-08-25; most recent amendment 2026-03-23.
Status change: Recruiting → Active, Not Recruiting 2023-03-17
Status change: Not Yet Recruiting → Recruiting 2021-01-04
Trial Details
NCT Number NCT04531046
Lead Sponsor The Lymphoma Academic Research Organisation
Conditions B-Cell Lymphoma Refractory, B-cell Lymphoma Recurrent
Enrollment 62 participants
Start Date 2021-03-10
Primary Completion 2022-04-19 (estimated)
Study Completion 2026-06 (estimated)
Updated on ClinicalTrials.gov 2026-03-27